About us

Our name Enara Bio™ is derived from an Arabic word meaning illumination, enlightenment and bringing light into the darkness.

We are the leaders in exploring the hidden depths of cancer and T-cell biology to discover and characterize Dark Antigens™, a novel class of shared immunotherapy targets that arise from altered cellular processes in cancer cells. We believe that Dark Antigens have the core attributes that will enable cancer immunotherapies to improve treatment outcomes for broad patient populations.

Enara Bio is backed by prominent life science investors, including RA Capital, Samsara Biocapital and SV Health Investors. We collaborate with world-leading companies and academic institutions, such as Boehringer Ingelheim and the Francis Crick Institute, to help drive our differentiated science-led approach.

Enara Bio Our Story Poster

Leadership Team

Andrew Fadden
Chief Business Officer
Kevin Pojasek
President and Chief Executive Officer
David Watson
Chief Operating Officer
Sophie Papa
Chief Medical Officer and Head of Translational Science
Joseph Dukes
Chief Scientific Officer

Board of Directors

Scientific Advisory Board

Mike Dybbs


Mike Dybbs has over 15 years of investment and consulting experience in the life science sector. He is currently a Partner at Samsara BioCapital where he invests across all stages of the life science sector from seed stage to public equities.

Prior to joining Samsara, Dr. Dybbs was a Partner at New Leaf Venture Partners. Before New Leaf, Dr. Dybbs was a Principal at The Boston Consulting Group, where he was a core member of their Health Care practice. Dr. Dybbs currently serves as a director of companies including: Enara Bio, IONpath, Levo Therapeutics, Nkarta Therapeutics and Sutro (STRO). Previously, he has served on the boards of companies including, Dimension Therapeutics (DMTX), Principia (PRNB) Versartis (VSAR), and Advanced Cell Diagnostics.

He earned a PhD in Molecular and Cellular Biology and Genetics from University of California, Berkeley, where he was awarded a Howard Hughes Medical Institute fellowship; and received an AB in Biomedical Sciences, magna cum laude, from Harvard University. His research had been published in peer-reviewed journals, including Science, Nature and Neuron.